COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study.
COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study.
复制标题
DOI：
10.1016/j.ijid.2020.11.198
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Askar MZ
中科院分区：
文献类型：
--
作者：
Alsharidah S;Ayed M;Ameen RM;Alhuraish F;Rouheldeen NA;Alshammari FR;Embaireeg A;Almelahi M;Adel M;Dawoud ME;Aljasmi MA;Alshammari N;Alsaeedi A;Al-Adsani W;Arian H;Awad H;Alenezi HA;Alzafiri A;Gouda EF;Almehanna M;Alqahtani S;Alshammari A;Askar MZ
研究COVID-19恢复期血浆（CCP）治疗中重度COVID-19疾病患者的有效性。这项非随机前瞻性队列研究于2020年5月21日至6月30日在科威特的四家主要三级医院进行。135例患者接受了CCP治疗。对照组包括233名接受标准治疗的患者。所有患者（N = 368，中位年龄54 [范围15 - 82]）均患有实验室确认的SARS-CoV-2感染和中度或重度COVID-19疾病。在中度或重度疾病患者中，CCP治疗与较高的临床改善率相关。在中度COVID-19疾病患者中，CCP组的临床改善时间为7天，而对照组为8天（p = 0.006）。对于严重的COVID-19疾病，CCP组的临床改善时间为7天，而对照组为15.5天（p = 0.003）。在校正分析中，中度疾病患者接受CCP治疗的30天死亡率显著降低。与对照组相比，氧饱和度在输注CCP后3天内改善，中度COVID-19疾病患者的淋巴细胞计数从第7天开始改善，重度疾病患者的淋巴细胞计数从第11天开始改善。在输注CCP后的前14天内，C反应蛋白水平下降。无一例CCP患者发生严重输血反应。数据显示，CCP给药是COVID-19疾病患者的安全治疗选择，在临床改善率和临床改善时间方面具有有利的结局。
To study the effectiveness of COVID-19 convalescent plasma (CCP) therapy for patients with moderate and severe COVID-19 disease. This non-randomized prospective cohort study was conducted from May 21 to June 30, 2020, at four major tertiary hospitals in Kuwait. CCP was administered to 135 patients. The control group comprised 233 patients who received standard treatment. All patients (N = 368, median age 54 [range 15–82]) had laboratory-confirmed SARS-CoV-2 infection and either moderate or severe COVID-19 disease. CCP treatment was associated with a higher rate of clinical improvement in patients with moderate or severe disease. Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CCP group, versus 8 days in the control group (p = 0·006). For severe COVID-19 disease, time to clinical improvement was 7 days in the CCP group, versus 15.5 days in the control group (p = 0·003). In the adjusted analysis, patients with moderate disease treated with CCP had a significantly lower 30-day mortality rate. Compared to the control group, oxygen saturation improved within 3 days of CCP transfusion, and lymphocyte counts improved from day 7 in patients with moderate COVID-19 disease and day 11 in patients with severe disease. C-reactive protein levels declined throughout the first 14 days after CCP transfusion. None of the CCP patients developed a serious transfusion reaction. The data show that administration of CCP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.
登录
查看更多内容
影响因子：
120.7
作者：
Li, Ling;Zhang, Wei;Liu, Zhong
通讯作者：
Liu, Zhong
影响因子：
1.2
作者：
Ko, Jae-Hoon;Seok, Hyeri;Peck, Kyong Ran
通讯作者：
Peck, Kyong Ran
影响因子：
15.9
作者：
Joyner, Michael J.;Wright, R. Scott;Casadevall, Arturo
通讯作者：
Casadevall, Arturo
使用恢复期血浆治疗 5 名 COVID-19 危重患者。
影响因子：
120.7
作者：
Shen, Chenguang;Wang, Zhaoqin;Liu, Lei
通讯作者：
Liu, Lei
DOI：
10.1016/j.tracli.2015.12.003
发表时间：
2016-02
期刊：
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
影响因子：
--
作者：
Garraud O;Heshmati F;Pozzetto B;Lefrere F;Girot R;Saillol A;Laperche S
通讯作者：
Laperche S